Serum sirtuin 1 levels in patients with polycystic ovary syndrome

References

• Angioni S, Porthegese E, Milano F, Melis GB. Fulghesu AM. 2008. Diagnosis of metabolic disorders in women with polycystic ovary syndrome. Obstetrical and Gynecological Survey 63:796–802.
   PubMed Web of Science ®Google Scholar
• Bhathena RK. 2011. Insulin resistance and the long-term consequences of polycystic ovary syndrome. Journal of Obstetrics and Gynecology 31:105–110.
   PubMedGoogle Scholar
• Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J et al. 2006. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biology 4:e31.
   PubMed Web of Science ®Google Scholar
• Fulghesu A, Magnini R, Portoghese E, Angioni S, Minerba L, Melis GB. 2010. Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome. Journal of Adolescent Health 46: 474–481.
   PubMed Web of Science ®Google Scholar
• Ichıkawa T, Hayashı R, Suzukı K, Imanıshı S, Kambara K, Okazawa S et al. 2013. Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. Respirology 18:332–339.
   PubMed Web of Science ®Google Scholar
• Galluzzo A, Amato MC, Giordano C. 2008. Insulin resistance and polycystic ovary syndrome. Nutrition, Metabolism, and Cardiovascular Disease 18:511–518.
   PubMed Web of Science ®Google Scholar
• Grubisha O, Smith BC, Denu JM. 2005. Small molecule regulation of Sir 2 protein diacetylases. FEBS Journal 272:4607–4616.
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. 2009. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Review Genetics 10:32–42.
   PubMed Web of Science ®Google Scholar
• Haigis MC, Guarente LP. 2006. Mammalian sirtuins emerging roles in physiology, aging, and calorie restriction. Genes and Development 20:2913–2921.
   PubMed Web of Science ®Google Scholar
• Jiang WJ. 2008. Sirtuins: novel targets for metabolic disease in drug development. Biochemical and Biophysical Research Communications 373:341–344.
   PubMed Web of Science ®Google Scholar
• Kong S, Yeung P, Fang D. 2013. The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis. Journal of Genetics and Genomics 40:347–354.
   PubMed Web of Science ®Google Scholar
• Lomb DJ, Laurent G, Haigis MC. 2010. Sirtuins regulate key aspects of lipid metabolism. Biochimica et Biophysica Acta 1804:1652–1657.
   PubMed Web of Science ®Google Scholar
• Lugrin J, Ciarlo E, Santos A, Grandmaison G, dos Santos I, Le Roy D et al. 2013. The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock. Biochimica et Biophysica Acta 1833:1498–1510.
   PubMed Web of Science ®Google Scholar
• Martins IJ, Wilson AC, Lim WLF, Laws SM, Fuller SJ, Martins RN. 2012. Sirtuin-1 mediates the obesity induced risk of common degenerative diseases: Alzheimer's disease, coronary artery disease and Type 2 diabetes. Health 4:1448–1456.
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419.
   PubMed Web of Science ®Google Scholar
• Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A et al. 2012. Low levels of 25 (OH) D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clinical Nutrition 31:476–480.
   PubMed Web of Science ®Google Scholar
• Osborne B, Cooney GJ, Turner N. 2013. Are sirtuindeacetylase enzymes important modulators of mitochondrial energy metabolism? Biochimica et Biophysica Acta. pii:S0304-4165(13)00360-7.
   Google Scholar
• Schug TT, Li X. 2011. Sirtuin 1 in lipid metabolism and obesity. Annals of Medicine 43:198–211.
   PubMed Web of Science ®Google Scholar
• Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, Fessler MB et al. 2010. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Molecular and Cellular Biology 30:4712–4721.
   PubMed Web of Science ®Google Scholar
• Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. 2011. Histone diacetylases as regulators of inflammation and immunity. Trends in Immunology 32:335–343.
   PubMed Web of Science ®Google Scholar
• Shımoyama Y, Suzukı K, Hamajıma N, Nıwa T. 2011. Sirtuin 1 gene polymorphisms are associated with body fat and blood pressure in Japanese. Translational Research 157:339–347.
   PubMed Web of Science ®Google Scholar
• Silva JP, Wahlestedt C. 2010. Role of Sirtuin 1 in metabolic regulation. Drug Discovery Today 15:781–791.
   PubMed Web of Science ®Google Scholar
• Sirmans SM, Pate KA. 2013. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology 18:1–3.
   Google Scholar
• Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, Zhai Q. 2007. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metabolism 6:307–319.
   PubMed Web of Science ®Google Scholar
• Pfluger P.T, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. 2008. Sirt1 protects against high-fat diet-induced metabolic damage. Proceedings of the National Academy Science of the United State of America 105:9793–9798.
   Google Scholar
• Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1 alfa and SIRT 1. Nature 434:113–118.
   PubMed Web of Science ®Google Scholar
• Rodgers JT, Puigserver P. 2007. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proceedings of the National Academy Science of the Unite State of America 104:12861–12866.
   Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19–25.
   Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. 2010. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine 8. doi:10.1186/1741-7015-8-41
   PubMed Web of Science ®Google Scholar
• Unluhizarci K, Kaltsas G, Kelestimur F. 2012. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism. Europena Journal of Clinical Investigation 42:86–94.
   PubMed Web of Science ®Google Scholar
• Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov A et al. 2009. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nature Medicine 15: 206–210.
   PubMed Web of Science ®Google Scholar
• Yoshino J, Mills KF, Yoon MJ, Imai S. 2011. Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism 14:528–536.
   PubMed Web of Science ®Google Scholar
• Xie J, Zhang X, Zhang L. 2013. Negative regulation of inflammation by SIRT1. Pharmacological Research 67:60–67.
   PubMed Web of Science ®Google Scholar
• Xiong YL, Liang XY, Yang X, Li Y, Wei LN. 2011. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology 159:148–150.
   PubMed Web of Science ®Google Scholar